^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anal Carcinoma

    4d
    RC09-FIAS: The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery (clinicaltrials.gov)
    P=N/A, N=520, Recruiting, The First Hospital of Jilin University | Not yet recruiting --> Recruiting
    Enrollment open
    17d
    GI22-588: Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer (clinicaltrials.gov)
    P2, N=23, Recruiting, Dustin Deming | Trial completion date: Apr 2027 --> Apr 2029 | Trial primary completion date: Dec 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel
    17d
    Populational analysis of the mortality-to-incidence ratio across 20 cancer groupings in the Russian Federation. (PubMed, J Glob Health)
    This suggests that population-level differences in MIR and subsequent cancer outcomes are influenced by region, culture, and socioeconomic variations. These findings may inform public health policy on intersectional disparities in MIR across different populations in the Russian Federation, with applicability to other countries.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    18d
    PEACHES 2: Improving Clinic Delivery of HIV-related Anal Health Services (clinicaltrials.gov)
    P=N/A, N=8, Not yet recruiting, Albert Einstein College of Medicine
    New trial
    23d
    FRACAS: Towards an Understanding of Barriers and Delays in the Diagnosis of Anal Cancer (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Centre Hospitalier Intercommunal Creteil
    New trial
    25d
    Detecting HPV DNA in Anal and Cervical Cancers (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, University of Chicago | Suspended --> Recruiting
    Enrollment open
    1m
    Challenges and limitations of anal cancer and precancer screening among people with HIV in a real-world setting. (PubMed, Infection)
    Routine anal-cytology screening in an unsystematically selected cohort of 434 PWH contributing 1,383 person-years of F/U identified 7 cases of high-grade precancerous lesions and 1 asymptomatic AC. Important challenges included low uptake, limited specificity of cytology, inconsistent adherence to F/U recommendations, and insufficient availability of HRA. Improved communication of HIV-care-providers with all involved parties will be a key requirement for improving efficiency and outcomes.
    Journal • Real-world evidence
    |
    CD4 (CD4 Molecule)
    1m
    Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma. (PubMed, Nat Commun)
    During surveillance, ctDNA re-emergence precedes clinical or radiographic relapse in every case. These findings support the consideration of ctDNA as a dynamic, treatment-responsive biomarker warranting prospective validation for risk-adapted surveillance and adjuvant therapy in ASCC.
    Journal • Circulating tumor DNA
    |
    Signatera™
    1m
    Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes (clinicaltrials.gov)
    P=N/A, N=360, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    1m
    HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Jennifer Dorth
    New P2 trial • Circulating tumor DNA
    |
    IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • DPYD (Dihydropyrimidine Dehydrogenase)
    |
    capecitabine • Zynyz (retifanlimab-dlwr)
    1m
    Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls (clinicaltrials.gov)
    P=N/A, N=8670, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    1m
    Comparison of Whole-Viral Genome Sequencing and PCR-based assay for Anal HPV Detection to Inform Clinical Implementation. (PubMed, J Virol Methods)
    In addition, WGS-based identification of HPV16 sub-lineages demonstrated that the composite A1, A2, A4, and C1 sub-lineages were associated with a higher risk of abnormal cytology compared to other HPV16 sub-lineages. WGS can further delineate the natural history of anal HR-HPV and their sub-lineages in populations at high-risk for HPV acquisition.
    Journal
    |
    cobas® HPV test